Stock RGNX REGENXBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

News REGENXBIO Inc.

Equities

RGNX

US75901B1070

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
14.34 USD -0.07% Intraday chart for REGENXBIO Inc. -3.89% -20.11%
May. 15 Transcript : REGENXBIO Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
May. 15 HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : REGENXBIO Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating
MT
Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
REGENXBIO to Participate in Upcoming Investor Conferences
AQ
REGENXBIO to Participate in Upcoming Investor Conferences
PR
UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating
MT
Regenxbio: Q1 Earnings Snapshot
AQ
Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024
Earnings Flash (RGNX) REGENXBIO Posts Q1 Revenue $15.6M
MT
REGENXBIO Inc. Announces Consolidated Impairment Charges for the First Quarter Ended March 31, 2024
CI
REGENXBIO Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
PR
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PR
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition
AQ
One-time gene therapy could improve wet AMD
AQ
REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
CI
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
PR
Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03:30 PM
Transcript : REGENXBIO Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 through Mar-14-2024
HC Wainwright Initiates REGENXBIO With Buy Rating, $36 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGNX Stock
  4. News REGENXBIO Inc.